An Australian Listed Company Pharmaust ASXAA has released today.
They are eagerly awaiting commencing Phase I Human Trial for a Covid 19 Oral Treatment..
PAA;ASX released further data today that confirmed Monepantel and Monepantal Sulfone
demonstrated significant benefits against SARs 1 and SARs 2 based Virus.
July 26 (Reuters) - Pharmaust Ltd (PAA) :
MONEPANTEL AND MONEPANTEL SULFONE SIGNIFICANTLY PROTECT AGAINST COVID-19 VIRUS
MEDIATED CELL DEATHMPL AND MPLS APPEAR TO INHIBIT VIRAL INFECTION BY TARGETING
LATE-STAGE EVENTS IN COVID-19 VIRUS LIFE-CYCLEEVALUATION OF MPL IN COVID-19
PATIENTS BEING ASSESSED IN EUROPE FOR WHEN GMP GRADE TABLETS ARE MADE
The Company has Tablet production underway and is communicating with CRO's Corporate Research Organisations
seeking a Registered Clinical site capable of Trialing Monepantel MPL is a Regulated clinical environment In Vivo ( Human Trial Candidates )
The benefits of an Oral Treatment for Covid 19 allows for greater robust delivery where temperature controlled fluid vaccines are difficult to transport.
Also Oral Tablet form would not have to be administered by clinicians and allows for airdrop into remote locations.
The Update from Pharmaust reiterates the previous positive results from Trialing at the prestigious WEHI Institute where Marc Pelligrinin an Australian leading virologist commented "the results from testing MPL against Covid are simply remarkable"
The Viral Load reduction was a staggering 50% in the first 24 hours growing to 95% reduction in Viral Load with in 72 hours.
Infection Viral load Reduction from 31,762 mpl reduced to 469 mpl.... in a 72 hour period.
so far the data indicates MPL has the ability to be delivered during and prior to viral load (Infection occurring)
The Company is awaiting further news of Tablet delivery to progress further In Vivo Trialing .
Exciting times ahead for this company as Trialing on K9's with Lymphoma Cancers has delivered positive results that
have paved the way for Human Trialing
Monepantel the companies lead drug candidate will also commence trialing against MND with the ANZCTR
application already filed.....
The company is also awaiting results from the Olivia Newton John Foundation for Cancer with MPL being trialed
in depth against multiple Human cancers,,, hoping to replicate the previous ONJF results where MPL demonstrated
cancer fighting ability in 26 of 30 Human Cancers..
- Forums
- ASX - By Stock
- PAA
- Oral Treatment for Covid 19, Human Phase I Trials
Oral Treatment for Covid 19, Human Phase I Trials
-
- There are more pages in this discussion • 132 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PAA (ASX) to my watchlist
(20min delay)
|
|||||
Last
20.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $99.76M |
Open | High | Low | Value | Volume |
20.5¢ | 20.5¢ | 20.0¢ | $86.39K | 425.8K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
4 | 245685 | 20.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
20.5¢ | 204582 | 4 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
4 | 245685 | 0.200 |
6 | 229570 | 0.195 |
4 | 155324 | 0.190 |
11 | 505988 | 0.185 |
10 | 549536 | 0.180 |
Price($) | Vol. | No. |
---|---|---|
0.205 | 204582 | 4 |
0.210 | 302539 | 9 |
0.215 | 276995 | 8 |
0.220 | 734043 | 11 |
0.225 | 232889 | 5 |
Last trade - 16.10pm 10/10/2024 (20 minute delay) ? |
Featured News
PAA (ASX) Chart |
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham, MD & CEO
James Graham
MD & CEO
Previous Video
Next Video
SPONSORED BY The Market Online